Evotec SE

As of June 30, 2026, Evotec SE carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Evotec SE's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Evotec SE has 177.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.41, and the price-to-book ratio stands at 1.52.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.15B versus a market cap of 1.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Evotec SE maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.50, indicating elevated leverage, while an interest coverage ratio of -20.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Evotec SE posted a negative return on equity (ROE) of -26.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.65, reflecting losses generated across the asset base. The company generates approximately 177,317.11 in revenue per employee across its workforce of 4,621.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 17.56 indicates how many times Evotec SE sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Evotec SE recorded 15.14M in income tax expense. The company reported a pretax loss of -209.98M and -225.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 5, 2026, Evotec SE's stock has declined approximately 54.30% over the past 52 weeks. The 50-day moving average sits at 13.04, while the 200-day moving average is 22.87.

Over the twelve months ended June 30, 2026, Evotec SE generated 819.47M in revenue and converted that into -225.12M in net income, yielding earnings per share of -1.27. EBITDA reached -277.74M, while operating income came in at -163.54M.

As of June 30, 2026, Evotec SE holds 552.52M in cash and equivalents against 543.66M in total debt, resulting in a net debt position of 75.36M. Total book value stands at 760.40M, with working capital of 475.75M providing operational flexibility.

Evotec SE produced -131.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -67.09M in capital expenditures, free cash flow totaled -198.51M - equivalent to -1.12 per share.

Over the twelve months ended June 30, 2026, Evotec SE posted a gross margin of 10.49, reflecting its pricing power and cost economics. The operating margin of -19.96 and net profit margin of -27.47 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Evotec SE paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -17.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Evotec SE shareholders.

Evotec SE's most recent stock split took place on June 10, 2005.

As of June 30, 2026, Evotec SE has an Altman Z-Score of 0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.